Lumida
/ABT
⌘K
Abbott Laboratories

Abbott Laboratories

ABT
$101.95USD-1.36%-1.41 today

MARKET CAP

176.4B

P/E (TTM)

28.5x

FWD P/E

DAY RANGE

$101 – $104

52W RANGE

$82
$137

AI Summary

Stalk
TrimMedium

ABT remains in a Stage 4 decline, with price decisively breaking below key support and trading below all major moving averages. The medium-term posture is bearish, reinforced by a Support Failure pattern and no signs of oversold exhaustion. Short-term conditions are extended and lack divergence, suggesting deferral of aggressive selling (Trim) in line with the Stable strategy’s controlled patience.

  • Q2 revenue $10.5B (+4.8% YoY) accelerated to mid-single digits
  • Declared 410th consecutive $0.63 dividend, yielding 0.88%
  • Weak profitability factors and low earnings yield pressure returns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$43.1B$43.7B$40.1B$42.0B$44.3B
YoY %+24.5%+1.3%-8.1%+4.6%+5.7%
P / Sales5.8x4.4x4.8x4.7x4.9x
EV / Sales6.5x5.1x5.5x5.3x5.5x
Gross Profit, Adj.$24.5B$24.5B$22.1B$23.2B$25.0B
YoY %+25.2%-0.1%-9.7%+5.0%+7.6%
Margin %57.0%56.1%55.2%55.4%56.4%
EV / Gross Profit11.5x9.0x9.9x9.6x9.7x
EBITDA, Adj.$12.0B$11.6B$9.7B$10.0B$11.2B
YoY %+37.8%-2.8%-16.4%+3.3%+11.2%
Margin %27.8%26.6%24.2%23.9%25.2%
EV / EBITDA23.5x19.0x22.5x22.2x21.8x
EBIT$8.4B$8.4B$6.5B$6.8B$8.1B
YoY %+57.3%-0.7%-22.5%+5.4%+18.0%
Margin %19.6%19.2%16.2%16.3%18.2%
EV / EBIT33.4x26.4x33.7x32.6x30.2x
Net Income$7.1B$6.9B$5.7B$13.4B$6.5B
YoY %+57.3%-2.0%-17.5%+134.2%-51.3%
Net Margin16.4%15.9%14.3%31.9%14.7%
EPS (GAAP)$3.94$3.91$3.26$7.64$3.72
YoY %+56.3%-0.8%-16.6%+134.4%-51.3%